Inflammatory Compound Articles & Analysis: Older

3 news found

Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)

Pharmaceutical Assets Include Company’s Non-Opioid Anti-inflammatory Compound KLS-13019 to Treat Chemotherapy Induced Peripheral Neuropathy (CIPN) Company’s Strategy is to Utilize the Phase 2 Study Grant Funds to Complete Preclinical Studies in CIPN and Ready the Company to Begin FDA Phase 1 Human Clinical Trials DOYLESTOWN, PA / ACCESSWIRE / September 28, 2021 / Neuropathix, Inc. ...

Sep. 28, 2021

ByNeuropathix, Inc.

Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization of the Company’s Over-The-Counter Cosmeceutical Assets

Cosmeceutical Assets Include Company’s Lead Anti-inflammatory OTC Cosmeceutical Compound called LEA™ (Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine) Company’s Strategy is to Enable Dermique to Focus on Commercializing Near Term Revenue Drivers like LEA™, Other Cosmeceuticals DOYLESTOWN, PA / ACCESSWIRE / August 24, 2021 / Neuropathix, Inc. (“Neuropathix” ...

Aug. 24, 2021

ByNeuropathix, Inc.

Is a Cancer Breakthrough Living at the Bottom of the Sea?

When Eduardo Esquenazi was 28, he abruptly went from being a semiprofessional surfer and UC San Diego doctoral student to a patient at Memorial Sloan Kettering Cancer Center in New York. Diagnosed with testicular cancer, Esquenazi put his neurobiology studies on hold to embark on an intense treatment plan that included multiple rounds of chemotherapy. It turned his world upside down, but it ...

Dec. 23, 2016

BySirenas

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you